Be a more knowledgeable, successful laboratory in just five minutes each week!
Sign up to receive Dark Daily, a free email newsletter with laboratory news, strategies, tips, and techniques and get the Special Report: 2008 Trends in Clinical Laboratory Pathology Management free when you sign up.
Laboratory News
First Diagnostic Test for Alzheimer's and Parkinson's Disease Available Late 2008
A new blood test has been developed by a company that claims
it can give an early diagnosis of neurodegenerative disease and distinguish
between Parkinson's and Alzheimer's disease.
The test, called NuroPro,
comes from Power3Medical Products,
an Oklahoma-based proteomics company.
Power3 Medical Products has identified and patented several
blood proteins associated with neurodegenerative disease. NuroPro measures a suite of 59 protein
biomarkers, the relative levels of which can help distinguish between
Parkinson's, Alzheimer's and Lou Gehrig's disease, or tell if a patient is
disease-free. The company says the test
is highly accurate, with a specificity and sensitivity in the high 90s.
"There is currently no diagnostic test for any
neurodegenerative disease on the market-diagnoses are currently based solely on
a clinical diagnosis of symptoms," said Power3Medical CEO, Steve Rash.
Two clinical validation studies are currently underway at
the Cleo Roberts Center
of Clinical Research in Arizona in the United
States and at the Research Institute of Thessaly in Greece. The U.S. clinical validation study includes
one hundred Alzheimer's disease patients, one hundred Parkinson's disease
patients, and one hundred controls. Power3Medical
Products plans to sell the test when the clinical trials are finished. It should be available in Greece by Q3 of 2008 and in the U.S.
market by late Q3 or Q4 of 2008.
According to the Alzheimer's Association, as many as 5.2 million
people in the United States
are living with Alzheimer's. It is predicted that 10 million baby boomers will
develop Alzheimer's in their lifetime.
Furthermore, the direct and indirect costs of Alzheimer's and other
dementias to Medicare, Medicaid, and businesses amount to more than $148
billion each year.
Pathologists and lab directors will want to monitor the
arrival of this test in the clinical marketplace. It is an example of how multi-analyte assays,
based on genomic or proteomic technology, promise to deliver new tools for
diagnosing disease. Should the test demonstrate
effectiveness in its clinical studies, there is likely to be significant demand
for it. Because the symptoms of
Alzheimer's, Parkinson's, and other neurodegenerative diseases are easily
confused with the normal effects of old age, a test that can provide an
accurate diagnosis is likely to be accepted and used by clinicians.
Related Articles:
